Cartesian Therapeutics, Inc. (RNAC) Stock Price & Analysis
Cartesian Therapeutics, Inc. (RNAC) closed at USD 6.58 on Thursday, October 15, 2026, up 3.79% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.34; the Oct 15, 2026 session ranged USD 6.39–6.78 on volume of 86,765 shares. Market capitalization is $199.08M, with a 52-week range of USD 5.6–11 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RNAC.md
Key facts (RNAC)
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 33.67 (range 16–44).
- Total return with dividends: 1Y -30.1% vs S&P 500 +18.1%; 5Y -94.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.01, revenue estimate $121K.
Analysts (RNAC)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 33.67 (low 16, high 44).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-09-29 | Needham | Reiterated | Buy | $40 |
| 2026-08-18 | Wedbush | Reiterated | Outperform | $38 |
Total return (dividends reinvested) (RNAC)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -30.1% | -94.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -30.2% | -44.7% |
| Volatility (annualized) | 81.3% | 93.2% |
| Max drawdown | -40.1% (Jul 2026→Oct 2026) | -95.4% (Oct 2021→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 6.58 |
|---|---|
| Change | ▲ 3.79% (up) |
| Previous Close | USD 6.34 |
| Open | USD 6.39 |
| Day Range | USD 6.39 – 6.78 |
| 52-Week Range | USD 5.6 – 11 |
| Volume | 86,765 shares |
| Market Cap | $199.08M |
| Exchange | NGM |
Technical Analysis (RNAC)
Nexqual's technical model rates RNAC "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.6 (oversold) |
| vs SMA50 | Below (USD 8.33) |
| MACD | -0.49 (negative) |
Analyst Ratings (RNAC)
Wall Street analysts rate RNAC "Buy" based on 7 analysts, with a mean price target of USD 33.67 (range USD 16–44), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 33.67 |
| High Target | USD 44 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (RNAC)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $121,430 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.96 vs est -0.65 ▼ miss |
| 2026-03-31 | USD -0.95 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -2.71 vs est -0.79 ▼ miss |
| 2025-09-30 | USD -0.73 vs est -0.63 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (RNAC)
| Total Revenue | $1.48M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -6679.69% |
| Profit Margin | +0.00% |
| Current Ratio | 7.48 |
| Total Cash | $147.61M |
| Total Debt | $63.85M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$79.39M (-2838.6% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (RNAC)
Nexqual rates Cartesian Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -93% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $148M cash vs $64M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$79M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Mixed — No data |
Ownership (RNAC)
| Insider Ownership | +52.13% |
|---|---|
| Institutional Ownership | +29.45% |
| Shares Outstanding | 30.26M |
| Float | 11.49M |
| Short % of Float | +13.37% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (RNAC)
Cartesian Therapeutics, Inc. is led by Carsten Brunn (age 54), President, CEO & Chairman of the Board, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Chairman of the Board | Carsten Brunn (age 54) |
|---|---|
| Chief Financial Officer | Blaine T. Davis (age 51) |
| Chief Operating Officer | Emily English (age 45) |
Major Backers & Investors (RNAC)
Notable institutional backers of Cartesian Therapeutics, Inc. include Squarepoint Ops LLC, 683 Capital Management LLC, Fidelity, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Squarepoint Ops LLC | 7.45% |
| 683 Capital Management LLC | 2.15% |
| Fidelity | 1.92% |
| FMR, LLC | 1.22% |
| AQR Capital Management, LLC | 1.18% |
| Millennium Management | 1.02% |
| Two Sigma Investments, LP | 0.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.26% |
| Vanguard Group | 3.82% |
| Geode Capital | 1.18% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt